When teacher Ellen Reich began treatment for multiple myeloma in 2014, a sequence of therapies approved by the U.S....
For most solid tumors, traditional biopsies are the gold standard for diagnosing cancer and assessing molecular characteristics that may...
With the August 2020 U.S. Food and Drug Administration approvals of the Guardant 360 CDx and FoundationOne Liquid CDx...
Circulating tumor DNA (ctDNA) was first detected over 30 years ago, but its potential uses for cancer diagnosis and...
Liquid biopsies, noninvasive tests performed on biofluids to detect genetic alterations in tumors, are a recent revolution in the...
Cancer is the second leading cause of death globally, accounting for nearly 10 million deaths each year. Late-stage diagnosis is a major contributor of cancer-related mortality, as...
The second day of the AACR Virtual Annual Meeting II began with a clinical trials plenary session. Two of the session’s presentations, which focused on immunotherapy clinical...
Biopsies have been an integral part of cancer care for decades. In undiagnosed patients, oncologists can examine suspicious tissues...
As the 2018 Annual Meeting of the American Association for Cancer Research unfolded yesterday morning, the excitement among the...
On June 1, the U.S. Food and Drug Administration (FDA) approved a liquid biopsy test, a companion diagnostic test...
AACR is the proud Scientific Partner for Stand Up To Cancer (SU2C), and for Colorectal Cancer Awareness Month, we...